Bicara Therapeutics Inc. earnings releases BCAX

Annual Quarterly

Bicara Therapeutics Inc. last reported quarterly results on Aug 11, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$0.82. It usually reports 41–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 9, 2026.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 41–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Aug 11, 2026
42 days after quarter end
Q2 FY2026
ended Jun 30, 2026
—
-55
-102.4%
-0.82
-64.0%
May 11, 2026
41 days after quarter end
Q1 FY2026
ended Mar 31, 2026
—
-56
-52.6%
-0.93
-36.8%
Feb 26, 2026
57 days after quarter end
Q4 FY2025
ended Dec 31, 2025
—
-37
-78.4%
-0.00
+45.0%
Nov 10, 2025
41 days after quarter end
Q3 FY2025
ended Sep 30, 2025
—
-36
-107.8%
-0.67
+58.1%
Aug 12, 2025
43 days after quarter end
Q2 FY2025
ended Jun 30, 2025
—
-27
-0.50
May 13, 2025
43 days after quarter end
Q1 FY2025
ended Mar 31, 2025
—
-37
-0.68
Nov 12, 2024
43 days after quarter end
Q3 FY2024
ended Sep 30, 2024
—
-17
-1.60

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BCAX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
, Emerging growth company
SEC CIK
2023658

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.